Osaka, Japan & Cambridge, Mass., United States: − Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis− Takeda to receive exclusive global license in all territories outside of mainland China, Hong Kong and Macau− Transaction builds upon …
